Serum Institute of India (SII) will manufacture Russian vaccine Sputnik V in the country after the approval of the drug regulatory body Drug Controller General of India (DCGI). It will be manufactured at the Hadapsar facility of SII under certain conditions. The Pune-based company has tied up with Russia’s Gamaleya Research Institute of Epidemiology and Microbiology, Moscow. On Thursday, SII had sought DCGI’s approval in this regard. The Russian vaccine needs to be given at an interval of 21 days. According to Gamaleya, two doses of Sputnik V are 91% effective while one dose is 79.4% effective.
*Please create a profile first to EARN & REDEEM points
Serum Institute gets DCGI’s approval to manufacture Russian vaccine Sputnik V in India
We are building a board of industry expert to help us verify important news stories. If you would like to empanel yourself, please click here.